Bhowmick, N.; Akinsola, R.; Billet, S.; Muranaka, H.; Jacobs, J.P.; Abbas, A.; Moshayedi, N.; Placencio-Hickok, V.R.; Osipov, A.; Hendifar, A.E.; Gong, J. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support. Preprints2024, 2024010727. https://doi.org/10.20944/preprints202401.0727.v1
APA Style
Bhowmick, N., Akinsola, R., Billet, S., Muranaka, H., Jacobs, J.P., Abbas, A., Moshayedi, N., Placencio-Hickok, V.R., Osipov, A., Hendifar, A.E., & Gong, J. (2024). Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support. Preprints. https://doi.org/10.20944/preprints202401.0727.v1
Chicago/Turabian Style
Bhowmick, N., Andrew E Hendifar and Jun Gong. 2024 "Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support" Preprints. https://doi.org/10.20944/preprints202401.0727.v1
Abstract
Background: Although previous studies have implicated a role for the stool microbiome in cancer cachexia, the fecal microbiome has not been previously characterized for patients with pancreatic ductal adenocarcinoma (PDAC) and cachexia treated with nutritional interventions such as enteral feeding.
Methods: The PANCAX-1 (NCT02400398) prospective trial enrolled 31 cachectic advanced PDAC patients to receive jejunal tube peptide-based diet for 12 weeks who were planned for palliative chemotherapy. Out of 16 evaluable patients, 62.5% receiving enteral feeding met the primary endpoint of weight stability at 12 weeks. As part of an exploratory analysis of the PANCAX-1 trial, serial stool and blood samples were collected at 0 (C1D1), 6 (C2D1), and 12 (C3D1) weeks over the 12-week period of enteral feeding. Stool samples were analyzed using 16S v4 sequencing of the microbiome. Up to 219 plasma metabolites were analyzed by mass spectrometry and high-performance liquid chromatography.
Results: A total of 29 stool samples were prospectively collected from 16 subjects with PDAC enrolled in PANCAX-1 who were evaluable for weight stability. Over 12 weeks of enteral feeding, statistically significant increases in the abundance of bacterial genera such as Veillonella (p=0.0150) and Actinomyces (p=0.0390) were observed, while there was a lower abundance of Bacteroides (p=0.0150) and Butyricicoccus (p=0.0390). Greater abundance of Veillonella and reduced Bifidobacterium at baseline were linked to greater weight stability. Plasma metabolomics in 10 subjects showed that weight unstable patients had significantly decreased levels of essential (L-histidine, L-phenylalanine) and non-essential amino acids (L-citrulline, L-tyrosine, all p<0.05) at the end of 12 weeks of enteral feeding. High stool Veillonella abundance was significantly associated with increases in the nucleotide 2-deoxycytidine 5-diphosphate and essential amino acid L-isoleucine but decreased TCA cycle metabolite alpha-ketoglutarate (all p<0.05).
Conclusions: We are the first to demonstrate the feasibility of stool microbiome profiling and plasma metabolomics in paired stool and plasma samples from a prospective cohort of advanced PDAC patients on enteral feeding as their primary source of nutrition. Our findings are hypothesis-generating in that metabolites unique to weight stability and abundance of stool bacterial genera may inform future studies of anti-cachexia therapies involving enteral feeding or microbial modulation.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
